Saudi Pharmaceutical Industries and Medical Appliances Past Earnings Performance
Past criteria checks 0/6
Saudi Pharmaceutical Industries and Medical Appliances has been growing earnings at an average annual rate of 13.6%, while the Pharmaceuticals industry saw earnings growing at 11.4% annually. Revenues have been declining at an average rate of 0.07% per year.
Key information
13.6%
Earnings growth rate
13.6%
EPS growth rate
Pharmaceuticals Industry Growth | 12.4% |
Revenue growth rate | -0.07% |
Return on equity | -0.5% |
Net Margin | -1.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Not Lagging Industry On Growth Or Pricing
Mar 21Is Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Worth ر.س38.1 Based On Its Intrinsic Value?
Jun 26Is There An Opportunity With Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) 20% Undervaluation?
Mar 14Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) Intrinsic Value Is Potentially 52% Above Its Share Price
Aug 02Saudi Pharmaceutical Industries and Medical Appliances' (TADAWUL:2070) Dividend Is Being Reduced To ر.س0.60
May 19One Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Analyst Just Made A Major Cut To Next Year's Estimates
May 12A Look At The Fair Value Of Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070)
Feb 20Saudi Pharmaceutical Industries and Medical Appliances' (TADAWUL:2070) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 18Does It Make Sense To Buy Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) For Its Yield?
Mar 30Should Saudi Pharmaceutical Industries and Medical Appliances (TADAWUL:2070) Be Disappointed With Their 50% Profit?
Feb 23What You Need To Know About Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) Investor Composition
Jan 19Is Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) At Risk Of Cutting Its Dividend?
Dec 16Revenue & Expenses BreakdownBeta
How Saudi Pharmaceutical Industries and Medical Appliances makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,653 | -20 | 616 | 41 |
30 Sep 23 | 1,692 | -71 | 654 | 47 |
30 Jun 23 | 1,667 | -75 | 659 | 51 |
31 Mar 23 | 1,569 | -144 | 678 | 47 |
31 Dec 22 | 1,422 | -152 | 631 | 43 |
30 Sep 22 | 1,425 | -94 | 589 | 51 |
30 Jun 22 | 1,379 | -42 | 563 | 41 |
31 Mar 22 | 1,394 | 38 | 547 | 36 |
31 Dec 21 | 1,460 | 30 | 537 | 29 |
30 Sep 21 | 1,471 | 57 | 527 | 14 |
30 Jun 21 | 1,532 | 117 | 519 | 20 |
31 Mar 21 | 1,534 | 110 | 513 | 20 |
31 Dec 20 | 1,555 | 130 | 532 | 20 |
30 Sep 20 | 1,521 | -114 | 611 | 1 |
30 Jun 20 | 1,491 | -153 | 611 | 1 |
31 Mar 20 | 1,518 | -365 | 657 | 7 |
31 Dec 19 | 1,487 | -434 | 653 | 13 |
30 Sep 19 | 1,743 | -163 | 586 | 40 |
30 Jun 19 | 1,626 | -204 | 594 | 40 |
31 Mar 19 | 1,566 | 6 | 551 | 39 |
31 Dec 18 | 1,503 | 74 | 541 | 40 |
30 Sep 18 | 1,313 | 66 | 517 | 34 |
30 Jun 18 | 1,366 | 61 | 500 | 37 |
31 Mar 18 | 1,375 | 85 | 459 | 39 |
31 Dec 17 | 1,386 | 139 | 488 | 37 |
30 Sep 17 | 1,315 | 274 | 589 | 36 |
30 Jun 17 | 1,295 | 296 | 605 | 31 |
31 Mar 17 | 1,329 | 289 | 654 | 31 |
31 Dec 16 | 1,259 | 277 | 633 | 31 |
30 Sep 16 | 1,448 | 124 | 563 | 48 |
30 Jun 16 | 1,499 | 149 | 544 | 41 |
31 Mar 16 | 1,595 | 347 | 559 | 33 |
31 Dec 15 | 1,705 | 357 | 561 | 25 |
30 Sep 15 | 1,604 | 457 | 574 | 0 |
30 Jun 15 | 1,562 | 465 | 570 | 0 |
31 Mar 15 | 1,500 | 325 | 558 | 0 |
31 Dec 14 | 1,470 | 317 | 552 | 0 |
30 Sep 14 | 1,424 | 283 | 547 | 0 |
30 Jun 14 | 1,381 | 279 | 528 | 0 |
31 Mar 14 | 1,351 | 295 | 516 | 0 |
31 Dec 13 | 1,311 | 267 | 502 | 0 |
30 Sep 13 | 1,294 | 264 | 484 | 0 |
30 Jun 13 | 1,299 | 262 | 474 | 0 |
Quality Earnings: 2070 is currently unprofitable.
Growing Profit Margin: 2070 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2070 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.6% per year.
Accelerating Growth: Unable to compare 2070's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2070 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.8%).
Return on Equity
High ROE: 2070 has a negative Return on Equity (-0.54%), as it is currently unprofitable.